Neuron23
South San Francisco, United States · Biotechnology · 135 employees
Neuron23™ Inc. is a leading clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating
Funding history
- Series series d — $96.5M — Jun 2025
- Series series c — $100.0M — Mar 2022
Recent signals
- Jun 24, 2025: Raised $96.5M in Series series d
- Aug 22, 2023: Neuron23 Appoints Andrew Yost, MBA, as Chief Business Officer
- Mar 30, 2022: Raised $100.0M in Series series c
See plans & pricing → Track Neuron23’s funding, hiring, and signals — with verified contacts — on Fundz.